Zoran Culig
#165,209
Most Influential Person Now
Researcher
Zoran Culig's AcademicInfluence.com Rankings
Zoran Culigcomputer-science Degrees
Computer Science
#9842
World Rank
#10325
Historical Rank
Machine Learning
#4414
World Rank
#4464
Historical Rank
Artificial Intelligence
#4769
World Rank
#4832
Historical Rank
Database
#6794
World Rank
#7033
Historical Rank
Download Badge
Computer Science
Zoran Culig's Degrees
- PhD Computer Science University of Zagreb
- Masters Computer Science University of Zagreb
- Bachelors Computer Science University of Zagreb
Similar Degrees You Can Earn
Why Is Zoran Culig Influential?
(Suggest an Edit or Addition)Zoran Culig's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. (1994) (856)
- Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. (1993) (488)
- Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. (1998) (456)
- Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system (1999) (435)
- Prevention and early detection of prostate cancer. (2014) (357)
- Regulation of prostatic growth and function by peptide growth factors (1996) (324)
- Distant metastases from prostatic carcinoma express androgen receptor protein. (1995) (311)
- Interleukin‐6 regulation of prostate cancer cell growth (2005) (294)
- Interleukin-6 and prostate cancer progression. (2001) (289)
- Androgen receptors in prostate cancer. (2003) (250)
- Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. (1994) (247)
- The mutational landscape of prostate cancer. (2013) (230)
- Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. (2012) (222)
- Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines (2011) (201)
- Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue (2000) (194)
- Alternative mechanisms of miR-34a regulation in cancer (2017) (189)
- ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat (2015) (185)
- Androgen receptor signaling in prostate cancer (2014) (184)
- JAK-STAT signaling in cancer: From cytokines to non-coding genome. (2016) (169)
- Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. (2010) (168)
- Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. (1999) (167)
- Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides (2000) (166)
- Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. (2008) (165)
- Interleukin‐6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival (2007) (159)
- Interleukin-6: A multifunctional targetable cytokine in human prostate cancer (2012) (158)
- Androgen Receptor Cross-talk with Cell Signalling Pathways (2004) (146)
- Expression, structure, and function of androgen receptor in advanced prostatic carcinoma (1998) (145)
- STAT3 regulated ARF expression suppresses prostate cancer metastasis (2015) (141)
- Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. (2001) (138)
- Expression and function of androgen receptor coactivators in prostate cancer (2004) (135)
- DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction (1993) (134)
- Oxidative stress-related aging: A role for prostate cancer? (2009) (133)
- Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth (2002) (131)
- Androgen receptor – an update of mechanisms of action in prostate cancer (2000) (121)
- Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review (2019) (120)
- Androgen axis in prostate cancer (2006) (117)
- Androgen deprivation increases p300 expression in prostate cancer cells. (2007) (116)
- The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy (2017) (115)
- The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study (2011) (113)
- Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells (2010) (112)
- Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. (2003) (112)
- Androgen receptors in prostate cancer. (2002) (111)
- Stem‐Like Cells with Luminal Progenitor Phenotype Survive Castration in Human Prostate Cancer (2012) (110)
- Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. (2008) (110)
- Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer (2016) (109)
- The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1 (2007) (106)
- Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. (2005) (103)
- The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer (2004) (99)
- Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. (2009) (98)
- Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic (2001) (97)
- Long‐term androgen‐ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells (2004) (97)
- Cytokine disbalance in common human cancers. (2011) (96)
- Current mouse and cell models in prostate cancer research. (2013) (96)
- p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. (2005) (95)
- The role of epithelial–mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel‐resistant prostate cancer (2017) (91)
- Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell‐specific markers (1997) (88)
- Mutant androgen receptors in prostatic tumors distinguish between amino‐acid‐sequence requirements for transactivation and ligand binding (1995) (84)
- The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. (2003) (79)
- ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance (2020) (78)
- PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. (2012) (75)
- Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. (2014) (75)
- Interleukin-6 and prostate cancer: Current developments and unsolved questions (2017) (74)
- The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling (2017) (71)
- Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. (2006) (70)
- Role of the androgen receptor axis in prostate cancer. (2003) (66)
- Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. (2009) (65)
- Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer (2015) (64)
- Expression of androgen receptor coregulatory proteins in prostate cancer and stromal‐cell culture models (2000) (64)
- Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models (2018) (62)
- Interleukin‐6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase (2005) (59)
- Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. (1996) (57)
- Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways (2012) (57)
- Androgen receptor alterations in prostatic carcinoma (1994) (55)
- Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. (2007) (52)
- An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. (2004) (51)
- Androgen Receptor Mutations in Carcinoma of the Prostate (2001) (50)
- Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer (2015) (49)
- Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer (2016) (48)
- Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer (2016) (47)
- Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. (1998) (47)
- Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide (2016) (46)
- Expression of the gene for tear lipocalin/von Ebner's gland protein in human prostate (1996) (44)
- Androgen Receptor Gene Mutations in Prostate Cancer (1997) (43)
- Androgen receptor co-activators in the regulation of cellular events in prostate cancer (2012) (43)
- Activation of the androgen receptor by polypeptide growth factors and cellular regulators (2004) (43)
- Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. (2008) (43)
- Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer (2017) (42)
- SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. (2010) (42)
- Transcriptional coactivators p300 and CBP stimulate estrogen receptor‐beta signaling and regulate cellular events in prostate cancer (2011) (42)
- Targeting the androgen receptor in prostate cancer (2014) (41)
- Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328 (2006) (41)
- Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity (2001) (41)
- Inflammation, Microbiota, and Prostate Cancer. (2016) (40)
- SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer (2013) (40)
- Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. (2000) (40)
- Mechanism of Androgen Receptor Activation and Possible Implications for Chemoprevention Trials (1999) (39)
- Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors (1997) (39)
- Identification of genes involved in estrogenic action in the human prostate using microarray analysis. (2004) (37)
- The Molecular Evolution of Castration-resistant Prostate Cancer. (2016) (37)
- Expression and function of androgen receptor in carcinoma of the prostate (2000) (37)
- PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer (2015) (36)
- Nuclear exclusion of the androgen receptor by melatonin (2002) (35)
- Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. (2002) (35)
- SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells (2016) (33)
- A role for neurotensin in bicalutamide resistant prostate cancer cells (2007) (32)
- Antagonist/Agonist Balance of the Nonsteroidal Antiandrogen Bicalutamide (Casodex) in a New Prostate Cancer Model (2000) (32)
- Antiandrogens in prostate cancer endocrine therapy. (2004) (31)
- The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models (2018) (31)
- The androgen receptor pathway is by‐passed in prostate cancer cells generated after prolonged treatment with bicalutamide (2006) (30)
- Activity of retinoic acid receptor‐γ selectively binding retinoids alone and in combination with interferon‐γ in breast cancer cell lines (1997) (28)
- Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP) (2007) (27)
- Role of the protein tyrosine phosphatase SHP‐1 in Interleukin‐6 regulation of prostate cancer cells (2010) (27)
- PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells (2014) (27)
- Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? (1997) (26)
- Oligomeric proanthocyanidin complexes (OPC) exert anti‐proliferative and pro‐apoptotic effects on prostate cancer cells (2008) (26)
- Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer (2018) (26)
- Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells (1999) (26)
- Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer (2013) (26)
- IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 (2013) (25)
- IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer. (2015) (25)
- Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy (2015) (25)
- The “Aging Factor” Eotaxin-1 (CCL11) Is Detectable in Transfusion Blood Products and Increases with the Donor’s Age (2017) (24)
- Epithelial mesenchymal transition and resistance in endocrine-related cancers. (2019) (24)
- Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells (2009) (23)
- Inhibition of the acetyltransferases p 300 and CBP reveals a targetable function for p 300 in the survival and invasion pathways of prostate cancer cell lines (2011) (23)
- Characterisation of a collecting duct carcinoma by cytogenetic analysis and comparative genomic hybridisation. (1998) (23)
- Androgen receptor point mutations as the underlying molecular defect in 2 patients with androgen insensitivity syndrome. (1997) (23)
- Crinum Latifolium Leave Extracts Suppress Immune Activation Cascades in Peripheral Blood Mononuclear Cells and Proliferation of Prostate Tumor Cells (2011) (22)
- SOCS‐3 antagonizes pro‐apoptotic effects of TRAIL and resveratrol in prostate cancer cells (2011) (21)
- Suppressors of cytokine signalling-3 and -1 in human carcinogenesis. (2013) (21)
- Identification of µ‐crystallin as an androgen‐regulated gene in human prostate cancer (2009) (20)
- Androgen signal transduction and prostatic carcinoma (2004) (20)
- Interleukin-6 as a therapy target in oral squamous carcinoma (2013) (19)
- Words of wisdom: Re: TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. (2014) (19)
- Is Eotaxin‐1 a serum and urinary biomarker for prostate cancer detection and recurrence? (2015) (19)
- CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer (2019) (18)
- Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells (2015) (18)
- A reliable system for the culture of human prostatic cells (1997) (18)
- Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells (2018) (17)
- Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line (1998) (17)
- The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells (2019) (17)
- Toll-Like Receptor 3 in Solid Cancer and Therapy Resistance (2020) (15)
- Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. (2011) (15)
- Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer (2017) (15)
- Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression (2004) (14)
- Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot (2015) (14)
- The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1. (2016) (13)
- Thyroid and androgen receptor signaling are antagonized by μ‐Crystallin in prostate cancer (2020) (13)
- High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. (2016) (12)
- Lynch Syndrome: Its Impact on Urothelial Carcinoma (2021) (12)
- The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer (2021) (12)
- Androgen receptor alterations in patients with disturbances in male sexual development and in prostatic carcinoma. (1995) (12)
- p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer (2020) (11)
- Distinguishing indolent from aggressive prostate cancer. (2014) (11)
- Abstract 3350: Implications of the STAT6 pathway by interleukin-4 in prostate cancer (2012) (10)
- Analysis of a Mutant Androgen Receptor Offers a Treatment Modality in a Patient with Partial Androgen Insensitivity Syndrome (1998) (10)
- The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe (2020) (10)
- Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer (2020) (10)
- SOCS3 (suppressor of cytokine signaling 3) (2012) (10)
- Cutting Edge Therapies for Cancer in the 21st Century (2014) (9)
- Interleukin‐4 induces a CD44high/CD49bhigh PC3 subpopulation with tumor‐initiating characteristics (2018) (9)
- CXCL8, an underestimated "bad guy" in prostate cancer. (2013) (9)
- Interleukin-6 polymorphism: expression and pleiotropic regulation in human prostate cancer. (2005) (9)
- Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines. (1997) (9)
- Interleukin-6 Function and Targeting in Prostate Cancer. (2021) (9)
- Combined study of prostatic carcinoma by classical cytogenetic analysis and comparative genomic hybridization. (2001) (9)
- Mechanism of 2‐chloroadenosine toxicity to PC3 cell line (2006) (9)
- MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cells to EP300/CREBBP inhibitors. (2021) (8)
- Androgen Receptor Function in Prostate Cancer Progression (2007) (8)
- The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer. (2015) (8)
- New insights into the role of interleukin-6 in human prostate cancer. (2009) (8)
- Increased resistance to trail‐induced apoptosis in prostate cancer cells selected in the presence of bicalutamide (2007) (8)
- KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis (2022) (8)
- Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression (2016) (7)
- Studies on Steroid Receptor Coactivators in Prostate Cancer. (2018) (6)
- SOCS 3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells (2016) (6)
- Studies on androgen receptor mutations and amplification in human prostate cancer. (2003) (6)
- STAT3 in Prostate Cancer: Whom Should We Treat and When? (2017) (6)
- Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer (2021) (5)
- Correction Alternative mechanisms of miR-34a regulation in cancer (2018) (5)
- Amplification of 7p12 is Associated with Pathologic Non-Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. (2019) (5)
- Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells (2022) (5)
- Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway. (2006) (5)
- TMPRSS:ERG fusion in prostate cancer: from experimental approaches to prognostic studies. (2014) (5)
- Tumorigenesis and Neoplastic Progression PIAS 1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p 21 (2012) (5)
- IL 6 sensitizes prostate cancer to the antiproliferative effect of IFN a 2 through IRF 9 (2013) (5)
- Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis (2015) (5)
- Abstract 3: Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy (2015) (5)
- Involvement of interleukin‐1β mediated nuclear factor κB signalling pathways to down‐regulate prostate‐specific antigen and cell proliferation in LNCaP prostate cancer cells (2012) (5)
- Androgen receptor mutations in prostate cancer (1998) (4)
- IL-6 / STAT 3 / ARF : the guardians of senescence , cancer progression and metastasis in prostate cancer (4)
- CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma (2021) (4)
- Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures. (2018) (4)
- 2‐Chloroadenosine modulates PAR‐1 and IL‐23 expression and enhances docetaxel effects on PC3 cells (2008) (4)
- Androgen Receptor Structure and Prostate Cancer (1996) (3)
- miRNA as regulators of prostate carcinogenesis and endocrine and chemoresistance. (2021) (3)
- Novel Experimental Therapeutic Approaches for Prostate Cancer (2005) (3)
- TRANSCRIPTION FACTOR STAT5 SYNERGIZES WITH ANDROGEN RECEPTOR IN PROSTATE CANCER CELLS (2008) (2)
- Effects of sorafenib on proliferation of hormone-sensitive and hormone-insensitive prostate cancer cells. (2009) (2)
- Prostate Cancer (2018) (2)
- Words of wisdom: Re: Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. (2014) (2)
- Unoccupied prolactin binding components of the benign and malignant human prostate in a subclinical and clinical procedure. (2014) (2)
- Cells Treated Chronically with Interleukin-6 Expression of Prostate-Specific Antigen in Prostate Cancer Independent − p 300 Regulates Androgen Receptor (2005) (2)
- Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer (2019) (2)
- Androgen receptor signaling in prostate cancer (2014) (2)
- Manuscript Title: Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. (2021) (2)
- [Clinical consequences of androgen receptor malfunction]. (2004) (2)
- Role of IL-6 in Regulating the Androgen Receptor (2009) (2)
- Molecular aspects of prostate cancer (2012) (2)
- IL-6 causes multiple effects in androgen-sensitive and -insensitive prostate cancer cell lines (2011) (2)
- Re: stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. (2008) (2)
- Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer (2018) (2)
- CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer (2019) (1)
- [Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion]. (2009) (1)
- The Coactivators CBP and p300 in Androgen Independent Prostate Cancer (2005) (1)
- Inhibition of CDK8/CDK19 suppresses its pro-oncogenic effects in prostate cancer. (2022) (1)
- Akacid Medical Formulation Induces Apoptosis in Myeloid and Lymphatic Leukemic Cell Lines In Vitro and In Vivo (2015) (1)
- IL-4 Counteracts the Cytotoxic Effects of Peripheral Blood Mononuclear Cells on Hormone-sensitive Prostate Cancer Cells (2021) (1)
- Editorial comment on: human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP cells. (2010) (1)
- Prostatitis and Urethritis (1999) (1)
- Abstract 618: Implications of inhibition of steroid receptor co-activator-1 in human prostate cancer (2014) (1)
- Expression of the androgen receptor coactivator Bag1 is upregulated in prostate cancer (2003) (1)
- Toll-like receptor 3 (TLR3) overexpression induces invasion of prostate cancer cells, whereas its activation triggers apoptosis. (2022) (1)
- New directions in endocrine therapy: renewed interest in the androgen receptor (2008) (1)
- Ligand-Dependent and Independent Activation of the Androgen Receptor and Implications for Therapy (2004) (1)
- New possibilities for urinary molecular diagnostics (2016) (1)
- Fibroblast Growth Factors and Their Receptors in Metastases of Prostate and Other Urological Cancers (2001) (1)
- Transcription Factors STAT5 and STAT3 (2008) (1)
- Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients (2022) (1)
- Pathway in Prostate Cancer Cell Lines Kinase A Activator on the Mitogen-activated Protein Kinase Action of EGF , Insulin-like Growth Factor I , and a Protein Epidermal Growth Factor ( EGF ) Receptor Blockade Inhibits the Updated (1998) (1)
- The way towards understanding possible multiple functions of AR V7 in prostate cancer (2018) (1)
- Genetic markers in prostate cancer: progress and limitations. (2012) (1)
- Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer (2022) (1)
- Stimulation of growth of prostate cancer cells 22Rv1 through activation of the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase (2005) (1)
- Abstract 1622: Inhibition of the acetyltransferase p300 as a novel pro-apoptotic and anti-invasion approach for treatment of prostate cancer (2011) (1)
- Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination (2023) (1)
- ANDROGENS, PROTEIN KINASE A ACTIVATORS, AND GROWTH FACTORS USE DIFFERENT MECHANISMS TO ACTIVATE THE ANDROGEN RECEPTOR (1999) (1)
- Resistance to anti-hormonal therapy in prostate cancer (2019) (1)
- Abstract A191: Augmenting the therapeutic efficacy of oncolytic LCMV-GP pseudotyped vesicular stomatitis virus via modulation of the innate immune system (2016) (1)
- The bi-directional interaction of AR and IL6 signalling in the response to enzalutamide in prostate cancer cells (2016) (1)
- ANTISENSE ANDROGEN RECEPTOR OLIGODEOXY-NUCLEOTIDES: A NEW METHOD FOR INHIBITION OF PROSTATE TUMOR CELL GROWTH (1999) (0)
- The role of p300 in human prostate tumor-initiating cells and chemotherapy resistance (2018) (0)
- Nuclear exclusion of the androgen receptor by melatonin in prostate cancer cells (2002) (0)
- Activation of the androgen receptor by Oncostatin M cannot be inhibited by nonsteroidal antiandrogens (2002) (0)
- Endocrine-Related Cancer ( 2002 ) 9 155 – 170 Androgen receptors in prostate cancer (2002) (0)
- Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer (2017) (0)
- THE CENTRAL ROLE OF EGF RECEPTOR BLOCKADE IN THE INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASE PATHWAYS: IMPLICATIONS FOR PROSTATE CANCER THERAPY (1999) (0)
- American Journal of Clinical and Experimental Urology: Editorial Board (2013) e-Century Publishing Corporation. (2013) (0)
- Multiple roles of interleukin-6 in prostate cancer (2011) (0)
- Supplementary figure 3 PIAS1 (2013) (0)
- ESUR Lecture: Which biomarkers are ready to use in clinical practice? (2016) (0)
- The Expanded Poly-Q Length Within AR and AR Coregulator AIB1 and Their Clinical Implications (2002) (0)
- TUMORIGENESIS AND NEOPLASTIC PROGRESSION Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer (0)
- Centrosomal Proteins in Urothelial Tumors: New Pathways in Disease Pathogenesis. (2019) (0)
- Re: Lin28 Promotes Growth of Prostate Cancer Cells and Activates the Androgen Receptor Tummala R, Nadiminty N, Lou W, et al. (2014) (0)
- Antiproliferative and Proapoptotic Effects of Akacid-Medical-Formulation on Hematologic Cell Lines. (2006) (0)
- 13th Congress of the European Society for Urological Oncology and Endocrinology (1998) (0)
- Platinum Priority – Collaborative Review – Prostate Cancer (2013) (0)
- 942 TYROSINE KINASE INHIBITOR SORAFENIB INDUCES GROWTH INHIBITION AND APOPTOSIS OF HUMAN PROSTATE CANCER CELLS BY REGULATION OF CELL CYCLE AND CELL DEATH CONTROLLING PROTEINS AND BLOCKING OF THE AKT PATHWAY (2011) (0)
- Tumorigenesis and Neoplastic Progression Suppressor of Cytokine Signaling ( SOCS )-1 Is Expressed in Human Prostate Cancer and Exerts Growth-Inhibitory Function through Down-Regulation of Cyclins and Cyclin-Dependent Kinases (2010) (0)
- Epithelial-to-mesenchymal transition in a virally induced cancer. (2015) (0)
- Paracrine and autocrine stimulation in prostate cancer (1997) (0)
- p300 and CBP targeting in castration therapy resistant prostate cancer (2019) (0)
- Abstract 1020: p300 and CBP targeting in castration therapy resistant prostate cancer (2019) (0)
- [Diagnostic of prostate cancer: conventional and molecular or cell biological methods]. (2009) (0)
- Mass spectrometry based urinary biomarkers to distinguish non-significant from significant prostate cancer (2019) (0)
- μ-Crystalline as hormone antagonist in prostate cancer (2016) (0)
- Pre-existing cell subpopulations in primary prostate cancers display surface fingerprint of docetaxel-resistant cells (2021) (0)
- Interleukin-4 induces a CD 44 high / CD 49 b high PC 3 subpopulation with tumor-initiating characteristics † Running Title : IL-4 and CD 44 high / CD 49 b high tumor-initiating cells (2017) (0)
- Epidermal Growth Factor ( EGF ) Receptor Blockade Inhibits the Action of EGF , Insulin-like Growth Factor I , and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines 1 (1998) (0)
- Abstract 3554: The fungal metabolite galiellalactone inhibits ALDH positive prostate cancer cells (2010) (0)
- Accelerated in vivo growth of prostate tumours that up-regulate interleukin-6 is associated with diminished retinoblastoma expression and activation of the mitogen-activated protein kinase pathway (2003) (0)
- 358 Vascular endothelial growth factor autocrine loop in prostate cancer cells generated after prolonged treatment with interleukin-6 (2004) (0)
- Androgen receptor coactivator CBP is down-regulated by androgens in prostate cancer cells (2003) (0)
- Molecular Diagnostics of Diseases with Androgen Receptor Mutations (1999) (0)
- 87 BICALUTAMIDE-RESISTANT PROSTATE CANCER CELLS SHOW REDUCED SENSITIVITY TO TUMOUR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (2007) (0)
- Abstract 3138: IL-6/Stat3 signaling is an indispensable modulator of oncogene-induced cellular senescence (2014) (0)
- Androgen-Independent Induction of Androgen-Responsive Genes by Interleukin-6 Regulation (2013) (0)
- Interleukin-6 as a target in cancer (2010) (0)
- Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide. (2018) (0)
- Targeting Interleukin-6 for the Treatment of Castration-Resistant Prostate Cancer (2014) (0)
- 168 Increased micro vessel density in carcinoma of the prostate is associated with up-regulation of interleukin-6 (2004) (0)
- 585: The Androgen Receptor Coactivator CBP is Highly Expressed In Therapy-Resistant Prostate Cancer (2004) (0)
- 575 The androgen receptor coactivator CBP is highly expressed in therapy-resistant prostate cancer (2004) (0)
- INTERLEUKIN-6 EXERTS DIFFERENT EFFECTS ON PROLIFERATION AND SIGNAL TRANSDUCTION IN TWO ANDROGEN-SENSITIVE PROSTATE CANCER CELL LINES (2006) (0)
- KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis (2022) (0)
- Editorial overview: Progress in modelling, understanding of cellular biology, and therapy of prostate cancer (2020) (0)
- Correction Alternative mechanisms of miR-34a regulation in cancer (2018) (0)
- 7018 POSTER NFkB Activity Modulates the Oncogenic Potential of Stat3 in Prostate Cancer Development (2011) (0)
- Review for "Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder" (2021) (0)
- Androgen Receptor and Interleukin-6 Signaling In PCA Progression (2005) (0)
- Overcoming enzalutamide-resistance by specific knockdown of transcription-factor STAT5 in prostate cancer (2018) (0)
- 237 The multikinase inhibitor sorafenib suppresses AR expression and signaling and induces apoptosis of castration therapy-resistant prostate cancer cells (2012) (0)
- Identification of Potential Novel Candidates for Understanding Racial Differences in Prostate Cancer. (2019) (0)
- 5-Alpha Reductase Inhibitors in Prostate Cancer (2010) (0)
- 10 Androgens and proinflammatory cytokines in development and progression of prostate cancer (2011) (0)
- Authors' reply (1998) (0)
- The AR/NCOA1 signaling regulates prostate cancer migration by involvement of PRKD1 (2016) (0)
- Abstract 1711: Establishment and characterization of docetaxel resistant prostate cancer cell lines (2011) (0)
- C-REACTIVE PROTEIN AS A PROGNOSTIC MARKER FOR mCRPC (2012) (0)
- Tumorigenesis and Neoplastic Progression Suppressor of Cytokine Signaling-3 Antagonizes cAMP Effects on Proliferation and Apoptosis and Is Expressed in Human Prostate Cancer (2006) (0)
- The ability of human adipose tissue – derived mesenchymal stem cells ( AT-MSCs ) , engineered to express the suicide gene cytosine deaminase : : uracil phosphoribosyltrans (2009) (0)
- HUS1 as a Potential Therapeutic Target in Urothelial Cancer (2022) (0)
- Review Article ANDROGEN RECEPTORS IN PROSTATE CANCER (2003) (0)
- 165 Growth stimulation of 22 RV1 cells by interleukin-6 does not involve activation of signalling pathways of signal transducers and activators of transcription factors and mitogen-activated protein kinases (2004) (0)
- PROSTATE CANCER-MOLECULAR BIOLOGY, HORMONES AND GROWTH FACTORS (1996) (0)
- p300 up-regulation by docetaxel contributes to chemotherapy resistance in prostate cancer (2019) (0)
- Rapidly changing endocrine oncology research: personal reflection of the past, present and future times. (2013) (0)
- Vol. 35, 1999 (1999) (0)
- Endocrine regulation of prostate cancer growth (2006) (0)
- Mechanisms of radioresistance in prostate cells (2016) (0)
- Role of toll-like receptor 3 in prostate cancer therapy-resistance (2019) (0)
- DIFFERENTIAL REGULATION OF THE A-TYPE CYCLINS IN RESPONSE TO INTERLEUKIN-6 TREATMENT IS MEDIATED BY PI3K AKT AND MAP KINASE PATHWAYS IN LNCAP PROSTATE CANCER CELL LINE (2006) (0)
- ID: 263: Loss of IL-6/Stat3 signalling drives metastatic prostate cancer in mice and men (2015) (0)
- Abstract B237: Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. (2011) (0)
- Abstract 2001: Transcriptional integrator p300 in human prostate tumor-initiating cells (2018) (0)
- Subject Index Vol. 35, 1999 (1999) (0)
- Endocrine regulation of prostatic growth (2006) (0)
- Androgen Receptor Crosstalk with Cell Signaling Pathways (2003) (0)
- Prostate cancer cells resistant to anti-androgen treatment up-regulate cyclin-dependent kinase 4 levels (2003) (0)
- ACQUISITION OF AGONISTIC PROPERTIES OF BICALUTAMIDE IS ASSOCIATED WITH PROSTATE TUMOR PROGRESSION IN A NEW MODEL SYSTEM (1999) (0)
- 248 Up-regulation of androgen receptor expression in enzalutamide-resistant prostate cancer cells (2016) (0)
- Overcoming enzalutamide-resistance by inhibition of the transcription factor Stat5b in prostate cancer (2019) (0)
- Distant MÃ © tastasesfrom Prostatic Carcinoma Express Androgen Receptor Protein 1 (2006) (0)
- Knockdown of PIAS1 increases the sensitivity to radiotherapy in breast cancer (2018) (0)
- Supplementary figure 1 PIAS1 (2013) (0)
- C. E. Alken Preis 2007: Androgene stimulieren die Expression von SOCS-3 und bewirken die Inhibition der Proliferation und Sekretion (2009) (0)
- Abstract 5059: Androgenic signaling influences SOCS-3 in prostate cancer cells (2015) (0)
- 224 HPV detection and genotyping in non-muscle invasive bladder cancer by single-step PCR (HPV-L1) and reverse line blot (RLB) hybridization assay (2015) (0)
- Launching of american journal of clinical and experimental urology. (2013) (0)
- Abstract 1726: Androgenic regulation of the anti-apoptotic Bcl-2 family member Mcl-1 in prostate cancer cells. (2013) (0)
- In memoriam of Georg Bartsch, MD, Professor of urology (1942–2012) (2012) (0)
- 228 THE MULTIKINASE INHIBITOR SORAFENIB SUPPRESSES AR EXPRESSION AND SIGNALING AND INDUCES APOPTOSIS OF CASTRATION THERAPY-RESISTANT PROSTATE CANCER CELLS (2012) (0)
- Therapeutic Discovery Inhibition of the Acetyltransferases p 300 and CBP Reveals a Targetable Function for p 300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines (2011) (0)
- Abstract B62: Protein inhibitor of activated STAT1 (PIAS1) is expressed in prostate cancer and stimulates cellular proliferation through inhibition of p21 (2012) (0)
- Pencik et al 2015 suppl (2015) (0)
- Family aggregation and the risk of prostate cancer (1993) (0)
- 2335 SOLUBLE GP130 PROMOTES PROSTATE CANCER INVASION AND PROGRESSION IN AN IL-6 INDEPENDENT FASHION (2011) (0)
- Prostatic Carcinoma Express Androgen Receptor Protein 1 (2006) (0)
- 218: Bicalutamide-Resistant Prostate Cancer Cells Fail to Respond to Vitamin E-Mediated Growth Inhibition (2005) (0)
- Tumorigenesis and Neoplastic Progression Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200 c and miR-205 (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Zoran Culig?
Zoran Culig is affiliated with the following schools:
